

Accelerating a phase 1 oncology trial: The TIME Network's impact on patient enrollment

BACKGROUND

Early-phase clinical trials are a critical, high-stakes step in drug development. For life sciences companies, the journey from a promising compound to a first-in-human study is filled with operational hurdles that can delay timelines and inflate costs. Slow site activation and the immense difficulty of finding patients that meet stringent trial eligibility criteria are two of the most significant barriers.

By combining a pre-established clinical site network with its AI-powered platform, Tempus helps life sciences companies address these challenges, supporting efforts to accelerate early-phase programs and development timelines. This case study highlights how sponsors like Pathos AI are leveraging the Tempus TIME Trial Network to launch Phase 1 studies more efficiently, reaching critical milestones faster.

THE CHALLENGE

Overcoming the hurdles of early-phase clinical trials

Launching a Phase 1 oncology trial is a complex undertaking. The traditional process of identifying, contracting with, and activating clinical trial sites can take many months, consuming valuable resources before the first patient can even be considered. These bottlenecks represent more than just operational friction; they are major risk factors that can impede a company's ability to generate the crucial early data needed to secure further investment and advance a therapeutic candidate. For a life sciences company, every day lost to administrative delays or slow enrollment is a day further from achieving key clinical and business objectives.

THE TEMPUS SOLUTION

The TIME Trial Network

To address these challenges, Tempus developed the TIME Trial Network, a program designed to accelerate trial activation and enrollment. TIME is a network of clinical sites that are optimized for rapid study start-up. By leveraging a nationwide network of sites and Tempus' advanced technology infrastructure, TIME helps sponsors overcome common early-phase trial challenges.

The Time Network enables sponsors to:

- **Activate trials rapidly:** The network streamlines contracting and start-up workflows, reducing the time required to get a study off the ground to as few as ~10 business days for just-in-time trial activation.
- **Identify potentially eligible patients at scale:** Using Tempus' AI-enabled platform, the TIME Network can identify potentially eligible patients across its sites, even for trials with highly specific molecular criteria. This allows for precise feasibility assessments and helps build a cohort of potential candidates for enrollment.
- **Access a diverse network:** The network includes a mix of academic and community-based sites, expanding access for patients by bringing trials into their local communities and providing sponsors with a broad recruitment base.

This integrated approach shifts trial execution from a reactive, site-by-site process into a proactive, network-wide strategy.

THE IMPACT

Pathos AI doses the first patient in a trial for mCRPC

Pathos AI, an AI-driven drug development company, is developing pocenbrodib, a novel CBP/p300 inhibitor. The company's goal was to initiate a Phase 1b/2a clinical trial (NCT06785636) for patients with metastatic castration-resistant prostate cancer.

Of the 10 patients enrolled on this trial to date, Tempus helped identify 6 matches through the TIME network:

762 screened

88 matches

6 consents

6 enrollments

"By partnering with Tempus, Pathos AI utilized the TIME Trial Network to launch its study. Tempus' platform helped identify sites with access to a high volume of potentially eligible patients, and the network's streamlined infrastructure enabled rapid activation. As a result, Pathos AI successfully dosed the first patient in its trial, a critical milestone that provides momentum for its development program and demonstrates clinical progress to stakeholders and investors."

—Iker Huerga, MD, CEO, Pathos AI

THE TEMPUS ADVANTAGE

A strategic investment in speed and precision

For life sciences companies, speed and precision are paramount. The ability to efficiently launch a Phase 1 trial and generate early clinical data is fundamental to long-term success. The Tempus TIME Trial Network provides the infrastructure to help achieve these goals.

"We launched the TIME program to address the significant unmet need for rapid trial start-up and enrollment, which are two of the most significant bottlenecks in bringing new therapies to patients...We are thrilled to see sponsors leveraging the network to accelerate the development of new therapies for patients who need them most."

—Noelle Gaskill, General Manager of TIME, Tempus

An investment in the TIME Network is a strategic decision to support early-phase development. By addressing the core operational challenges of site activation and patient enrollment, Tempus empowers sponsors to reach critical milestones faster, build value in their programs, and ultimately accelerate the delivery of next-generation therapies to patients.

Case studies and past performance are not necessarily an indication of future results, and do not guarantee a similar outcome.